Snspd-DCS at 1064 NM for non-invasive monitoring of cerebral perfusion and intracranial pressure in the ICU

Active Cooperative Agreement Awarded Last action

Award ID
U01EB034228
Recipient
Awarding agency
Obligated
$2,934,352

Award facts

Completion date 63% complete
Place of performance
Charlestown, MA 02129, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Monitoring intracranial pressure (ICP) is the global standard of care following severe brain injury. The goal of monitoring and treating rises in ICP is to maintain adequate cerebral blood flow (CBF), thereby preventing secondary brain injury. ICP is measured by a small pressure-sensitive probe inserted through the skull, with risk of intracranial hemorrhage and infection, hence used only in the most critically ILL patients. More importantly, ICP probes do not directly measure CBF and critical closing pressure (crcp), the pressure where blood flow ceases, which is needed to correctly assess cerebral perfusion pressure (CPP). Therefore IT is not currently possible to separate benign ICP elevations from flow-limiting pressure spikes. A non-invasive monitor of ICP, CBF and crcp would enable targeted interventions that directly optimize cerebral perfusion and significantly expand the potential use cases for ICP monitoring. Diffuse correlation spectroscopy (DCS) has emerged as a viable tool to monitor CBF, crcp and ICP. To measure CBF, DCS quantify the timescale of fluctuations in the intensity of coherent, diffusely propagating near-infrared light, which are driven by the motion of red blood cells. DCS measures ICP based on the morphology of the pulsatile blood flow (pcbfi) and IT estimates crcp by means of a linear regression approach between pulsatile blood pressure and pcbfi. While successful proof of concept studies have been conducted by our group and others, the clinical translation of DCS in adults is currently hampered by the challenge of balancing the requirement for high brain sensitivity, which requires large source- detector separations, and the need for high signal to noise ratio (SNR) at high acquisition rates to capture detailed pulsatile blood flow data. Current DCS devices operate at 785 - 850 NM and are limited to separations of 2.5 CM, offering relatively low brain sensitivity, high risk of superficial physiology contamination, and requiring pulse- gated averages of 50-60 cardiac cycles to extract clean pcbfi signals due to limited SNR. Quantification of CBF is strongly affected by scalp blood flow and important morphological information needed to accurately quantify crcp and ICP is lost during the averaging. To overcome these limitations, we propose to partner with one of the pioneers of superconducting nanowire single photon detectors (snspd) technology, quantum opus, to develop a compact, low sonic and thermal emission 8 channel snspd unit, designed with costs, manufacturability and scalability in mind, that we will integrate with a state-of-the art 1064 NM laser system, heterodyne detection, and fast fpga correlator to offer bilateral DCS monitoring at 3.5 CM (>50% increase in brain sensitivity) with more than 200-fold increase in SNR with respect to current 785 - 850 NM DCS technology. We will demonstrate the feasibility and initial clinical utility of the snspd-DCS in 50 neuro-ICU patients and validate our CBF, crcp and ICP estimates against TCD, invasive ICP, hemedex, and patient outcomes. The successful realization of this state-of-the-art non-invasive cerebral perfusion and pressure monitor will enable guided management of patients resulting in improved neurological outcomes.

Transactions

Action Obligated Date
Amendment $825,337
Amendment $767,390
Amendment $670,370
Original award $671,255

Subawards

Subrecipient Amount Awarded
Brigham & Womens Hospital Inc. The overall project goal is develop, a non-invasive, bedside intracranial pressure and cerebral blood flow monitor using diffuse correlation spectroscopy with… $482,908
Quantum Opus LLC SNSPDs are emerging as the gold standard for detecting optical quantum signals for fundamental tests of physical theories1, city�scale quantum key… $620,845

Quick answers

Who received award U01EB034228?

U01EB034228 was awarded to The General Hospital Corporation by National Institute of Biomedical Imaging and Bioenginering (National Institutes of Health) on September 1, 2023.

How much is award U01EB034228 worth?

$2,934,352 has been obligated on U01EB034228.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login